132 related articles for article (PubMed ID: 34879742)
1. Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma.
Podkonjak T; Cranmer H; Scarisbrick J; McCarthy G; Lilley C; Cheng LI
J Comp Eff Res; 2022 Feb; 11(3):193-202. PubMed ID: 34879742
[No Abstract] [Full Text] [Related]
2. Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
Elsea D; Savage KJ; Lilley C; Lisano J; Liu J; Yu KS
Adv Ther; 2023 May; 40(5):2326-2338. PubMed ID: 36920744
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
Dummer R; Prince HM; Whittaker S; Horwitz SM; Kim YH; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown L; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Huen A; Walewski J; Wang Y; Lisano J; Richhariya A; Feliciano J; Zhu Y; Bunn V; Little M; Zagadailov E; Dalal MR; Duvic M
Eur J Cancer; 2020 Jul; 133():120-130. PubMed ID: 32502876
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Horwitz SM; Scarisbrick JJ; Dummer R; Whittaker S; Duvic M; Kim YH; Quaglino P; Zinzani PL; Bechter O; Eradat H; Pinter-Brown L; Akilov OE; Geskin L; Sanches JA; Ortiz-Romero PL; Weichenthal M; Fisher DC; Walewski J; Trotman J; Taylor K; Dalle S; Stadler R; Lisano J; Bunn V; Little M; Prince HM
Blood Adv; 2021 Dec; 5(23):5098-5106. PubMed ID: 34507350
[TBL] [Abstract][Full Text] [Related]
5. Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.
Barta SK; Liu N; DerSarkissian M; Chang R; Ye M; Duh MS; Surinach A; Fanale M; Yu KS
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):e21-e32.e4. PubMed ID: 37919137
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM; Kim YH; Horwitz SM; Dummer R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Trotman J; Taylor K; Dalle S; Weichenthal M; Walewski J; Fisher D; Dréno B; Stadler R; Feldman T; Kuzel TM; Wang Y; Palanca-Wessels MC; Zagadailov E; Trepicchio WL; Zhang W; Lin HM; Liu Y; Huebner D; Little M; Whittaker S; Duvic M;
Lancet; 2017 Aug; 390(10094):555-566. PubMed ID: 28600132
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Fleeman N; Houten R; Chaplin M; Boland A; Beale S; Dundar Y; McEntee J; Syndikus I
Pharmacoecon Open; 2020 Dec; 4(4):563-574. PubMed ID: 32207075
[TBL] [Abstract][Full Text] [Related]
9. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome.
Lewis DJ; Haun PL; Samimi SS; Vittorio CC; Villasenor-Park J; Barta SK; Landsburg DJ; Svoboda J; Nasta SD; Schuster SJ; Rook AH; Kim EJ
JAMA Dermatol; 2021 Mar; 157(3):317-321. PubMed ID: 33377934
[TBL] [Abstract][Full Text] [Related]
11. Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098-5106.
Blood Adv; 2024 May; 8(9):2243. PubMed ID: 38743412
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients.
Papadavid E; Kapniari E; Marinos L; Nikolaou V; Oikonomidi A; Georgakopoulos J; Stratigos A; Kouloulias V; Pappa V
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e223-e225. PubMed ID: 30821007
[No Abstract] [Full Text] [Related]
13. Long term survival, time to next treatment and CD30 expression in patients with advanced CD30
Gosmann J; Stadler R
J Dtsch Dermatol Ges; 2022 Apr; 20(4):514-517. PubMed ID: 35319153
[No Abstract] [Full Text] [Related]
14. Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Zinzani PL; Salles G; Moskowitz AJ; Santoro A; Mehta A; Barr PM; Mehta-Shah N; Collins GP; Ansell SM; Brody JD; Domingo-Domenech E; Johnson NA; Cunningham D; Ferrari S; Lisano J; Krajewski J; Wen R; Akyol A; Crowe R; Savage KJ
Blood Adv; 2024 May; 8(10):2400-2404. PubMed ID: 38531062
[No Abstract] [Full Text] [Related]
15. A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.
Hux M; Zou D; Ma E; Sajosi P; Engstrom A; Selby R; Benson E; Briggs A; Bonthapally V
J Health Econ Outcomes Res; 2017; 4(2):188-203. PubMed ID: 37661948
[No Abstract] [Full Text] [Related]
16. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
17. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL.
Feldman T; Zou D; Rebeira M; Lee J; Fanale M; Manley T; Rao S; Feliciano J; Harris M; Kansal A
Am J Manag Care; 2020 Feb; 26(2):e41-e49. PubMed ID: 32059099
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: a single-centre retrospective review.
Henderson Berg MH; Davison K; Popradi G
Br J Dermatol; 2022 Feb; 186(2):379-381. PubMed ID: 34608632
[No Abstract] [Full Text] [Related]
20. A Case Series on the Use of Brentuximab Vedotin for the Treatment of Mycosis Fungoides.
Kelly KA; Edenfield L; Seegars MB; Vaidya R; Feldman SR; Strowd LC
J Drugs Dermatol; 2023 Dec; 22(12):e33-e34. PubMed ID: 38051830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
